PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model

Abstract

Authors

S. Shukla D. Shah A. Martin N.A. Risebrough R. Kendall C.F. Vogelmeier I. Boucot L. Tombs L. Bjermer P. Jones E. Kerwin C. Compton F. Maltais D. Lipson A. Ismaila